the Impact of Transcutaneous Vagus Nerve Stimulation on Cardiovascular Events in Patients With Acute Myocardial Infarction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: transcutaneous vagus nerve stimulation, Sham (no implant).
- Who it may be relevant to
- Registry conditions: Acute Myocardial Infarction (AMI). Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Impact of Transcutaneous Vagus Nerve Stimulation on Cardiovascular Events in Patients With Acute Myocardial Infarction
Overview
The acute mortality rate of acute myocardial infarction (AMI) reduced significantly due to emergency reperfusion and subsequent treatment strategies. However, it remains a major cause of disability and death globally. Recent studies have shown that systemic inflammation is associated with infarct size and adverse clinical outcomes after myocardial infarction. Therefore, attenuating the inflammatory response may be a therapeutic target for acute coronary syndromes and improve clinical outcomes. Preclinical and clinical data indicate that vagus nerve stimulation (VNS) plays an important role in reducing the inflammatory burden and improving myocardial ischemia. However, more clinical evidence is needed to elucidate the role of VNS in patients with acute myocardial infarction and its impact on cardiovascular events. Therefore, this study aims to investigate the effect of vagal nerve modulation intervention through a prospective, randomized controlled clinical research method.
Interventions
- Device transcutaneous vagus nerve stimulation
The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions. The device is set with a pulse width of 200 microseconds and a pulse frequency of 20 hertz. The stimulation intensity is individually adjusted to above the perception threshold and below the discomfort level of 1 milliampere. - Device Sham (no implant)
Vagus nerve stimulation is delivered through a transcutaneous electrical nerve stimulation device by attaching an ear clip to the tragus. But no stimulation will be delivered. The sham stimulation will be performed twice daily, each session lasting for half an hour. The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions.
Primary outcome measures
- The occurrence of composite cardiovascular events at 3 months [Time frame: 3 months after the onset of AMI]
Secondary outcome measures (4)
- The occurrence of recurrent myocardial infarction, acute heart failure, ventricular arrhythmias, embolic events, and death at 3 months. [Time frame: 3 month after the onset of AMI]
- Changes in left ventricular ejection fraction (EF) at 3 months. [Time frame: 3 month after onset of AMI]
- Changes in BNP, IL-6, CRP and troponin-T on day 7. [Time frame: Day 7 after AMI]
- Changes in the 6-minute walk test at 3 month [Time frame: 3 months after the onset of AMI]
Eligibility criteria
\*\*Inclusion Criteria\*\*
- Age between 18 and 80 years old (including 18 and 80 years old).
- Patients with acute myocardial infarction who have undergone revascularization of the culprit vessel within 24 hours of onset.
- Willing to participate in this study and have signed the informed consent form.
\*\*Exclusion Criteria\*\*
- Hemodynamically unstable, with cardiogenic shock, requiring medication to maintain blood pressure and heart rate.
- Baseline systolic blood pressure <90 mmHg or diastolic blood pressure <40 mmHg.
- Average heart rate under monitoring <50 beats per minute.
- Patients with II or III degree atrioventricular (AV) block or sick sinus syndrome who have not had a permanent pacemaker implanted.
- Baseline (before the use of antiarrhythmic drugs) QTc interval ≥500 ms, PR interval >280 ms.
- Patients who are participating in other clinical studies.
- Other reasons deemed by the investigator as unsuitable for participation in this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06991283 · 2025YS-063